Rpg Life Sciences Limited

BSE: 532983 NSE: RPGLIFE
Rpg Life Sciences Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN L24232MH2007PLC169354 Incorporated 29 March 2007 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - NSE: RPGLIFE · BSE: 532983 Public Limited Company pharma
Data last updated
Market Cap
₹4,796 Cr
RPGLIFE · NSE
Share Price
₹3,050.60
+5.20% today
Revenue
₹708 Cr
FY 2025-26 · +14.0% YoY
EBITDA
₹127 Cr
Margin 18.0%
Net Profit
₹110 Cr
FY 2025-26 · -5.1% YoY
P/E (TTM)
42.8x
P/B 8.3x
ROE
20.3%
ROCE 26.6%
Debt / Equity
0.02
Interest cover 1.7x

About Rpg Life Sciences Limited

Data last updated: 25 September 2026

Rpg Life Sciences Limited is a public limited company based in Mumbai, Maharashtra, India. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 29 March 2007, the company has been in operation for over 19 years.

Registered with ROC Mumbai under CIN L24232MH2007PLC169354. Listed on BSE: 532983 and NSE: RPGLIFE.

Capital: an authorised share capital of ₹15 Cr and a paid-up capital of ₹13.23 Cr. Formerly known as Rpg Pharmaceuticals Limited. It is led by directors including Manojkumar Madangopal Maheshwari and Yugal Kishor Chothuram Sikri.

Last AGM: 16 July 2025. Financial statements filed for year ended 31 March 2025. Office: Rpg House 463 Dr. Annie Besant Road Worli, Mumbai, Maharashtra, India – 400030.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹707.52 Cr, a growth of 8.28% compared to the previous year. The net worth stands at ₹605.35 Cr (up 14.1% YoY). Total assets are valued at ₹636.2 Cr (up 18.26% YoY).

The company has a workforce of approximately 1,197 employees as per the latest available data.

The company is associated with 1 brand - Rpg Life Sciences. As per MCA filings, the company has open charges of ₹65.92 Cr and satisfied charges of ₹71.07 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website rpglifesciences.com.

Company Details of Rpg Life Sciences Limited
CIN L24232MH2007PLC169354
Registration Number 169354
Incorporation Date 29 March 2007
ROC Mumbai
Listing Status Listed (BSE: 532983, NSE: RPGLIFE)
Company Status Active
Date of Last AGM 16 July 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Ashok Nair Managing Director Manojkumar Madangopal Maheshwari Director Yugal Kishor Chothuram Sikri Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    rpglifesciences.com
  • Social Media
  • Registered Address
    Rpg House 463 Dr. Annie Besant Road Worli, Mumbai, Maharashtra, India – 400030
  • Industry
    Pharma, API Manufacturers, Drug Formulation & Development
Company report
Rpg Life Sciences Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Rpg Life Sciences Limited report

Financials, compliance, directors, charges, ownership and filings for Rpg Life Sciences Limited in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Rpg Life Sciences Limited

Rpg Life Sciences Limited has one previous CIN (Corporate Identification Number): U24232MH2007PLC169354. The current CIN is L24232MH2007PLC169354, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L24232MH2007PLC169354 Current
U24232MH2007PLC169354 Previous

Associated Brands with Rpg Life Sciences Limited

Rpg Life Sciences Limited operates one associated brand: RPG Life Sciences. These brands represent Rpg Life Sciences Limited's diversified market presence and brand portfolio.

Brand Description Website
RPG Life Sciences
Generics and APIs are manufactured by RPG Life Sciences. rpglifesciences.com

Business Activity of Rpg Life Sciences Limited

Rpg Life Sciences Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
Premium access

Business activity turnover details for Rpg Life Sciences Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Rpg Life Sciences Limited

Rpg Life Sciences Limited is audited by S R B C & CO LLP for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.

Name Status Appointment Date Cessation Date
S R B C & CO LLP Locked Locked Locked
Premium access

Complete auditor history for Rpg Life Sciences Limited

Appointment status, appointment dates, cessation dates, and historical auditor changes require an active report plan.

  • Appointment status
  • Appointment dates
  • Cessation dates
  • Auditor changes

Verified entity values are shown only after access is granted.

Board of Directors of Rpg Life Sciences Limited

Rpg Life Sciences Limited is currently managed by 13 directors, with 23 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Manojkumar Madangopal Maheshwari
Also directs: Algo Vantage Llp, Maheshwari Investors Private Limited, R J Investment Private Limited and 1 more
Director 06 Feb 2008 18 Years 7 Months Current
Yugal Kishor Chothuram Sikri
Also directs: Synokem Pharmaceuticals Limited, Aic-Nmims Incubation Centre
Director 01 May 2025 1 Years 4 Months Current
Harsh Vardhan Goenka
Also directs: Sri Parvathi Suthan Trading Company Llp, Allwin Apartments Llp, Swallow Associates Llp and 5 more
Director 06 Feb 2008 18 Years 7 Months Current
Rajat Bhargava
Also directs: Spencer International Hotels Limited, Raychem-Rpg Private Limited, Harrisons Malayalam Ltd and 2 more
Director 25 Jan 2021 5 Years 8 Months Current
Sachin Rajkumar Nandgaonkar
Also directs: Ajax Engineering Limited, Vibgyor Pixel Prints Private Limited, Sterlite Electric Limited and 1 more
Director 23 Jan 2015 11 Years 8 Months Current
Zahabiya Habil Khorakiwala
Also directs: Hz Trading & Services Llp, Hnz Trading & Services Llp, Wockhardt Limited and 5 more
Director 29 Oct 2015 10 Years 10 Months Current
Showing 6 of 13 current directors. View all directors

Financials of Rpg Life Sciences Limited FY 2025-26 filings available

Rpg Life Sciences Limited reported revenue of ₹707.52 Cr (up 8.28% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹708 Cr
+8.3% YoY
EBITDA
₹127 Cr
-11.9% YoY
Profit After Tax
₹110 Cr
-5.1% YoY
Net Worth
₹605 Cr
+14.1% YoY
Total Assets
₹636 Cr
+18.3% YoY
Total Debt
₹20.00 Cr

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25
Income statement
Revenue708653
Revenue growth+14.0%+9997.0%
EBITDA127144
EBITDA margin+18.0%+22.1%
Profit before tax154233
Net profit110116
Net profit margin+15.5%+17.7%
EPS (₹)69.64110.80
Balance sheet
Total assets636538
Net worth605531
Total debt20.000.00
Cash & bank192140
Net working capital322220
Cash flow
Cash from operations56.5077.86
Cash from investing85.84(41.80)
Cash from financing(20.58)(27.08)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue196177180182169143173
Revenue growth (YoY)+15.9%+23.6%+4.2%+9997.0%+9997.0%+9997.0%+9997.0%
Other income4.7013.503.4115.765.231153.31
EBITDA43.2932.8331.3439.0335.4725.4949.16
EBITDA margin+22.1%+18.6%+17.4%+21.5%+21.0%+17.8%+28.5%
Depreciation5.905.745.385.225.145.375.46
Interest0.630.390.250.120.130.180.12
Profit before tax41.4640.2029.1249.4535.4313546.89
Tax10.7010.306.9912.609.1417.5511.96
Net profit30.7629.9022.1336.8526.2911734.93
EPS (₹)18.6018.0813.3822.2815.9070.9621.12
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue708653582513440389376
Revenue growth+14.0%+12.4%+10.7%+16.0%+10.9%-0.8%+8.5%
EBITDA12714412910487.2570.9354.84
EBITDA margin+18.0%+22.1%+22.2%+20.2%+19.8%+18.2%+14.6%
Profit before tax15423311891.6873.1753.5836.45
Net profit11011686.8968.2150.8740.0132.94
Net profit margin+15.5%+17.7%+14.9%+13.3%+11.6%+10.3%+8.8%
EPS (₹)69.64110.8053.0140.9031.1324.1917.54
Balance sheet
Total assets636538382315263225194
Net worth605531375308256216177
Total debt20.000.000.000.010.942.0211.72
Cash & bank15714036.4757.0470.2640.751.11
Net working capital28722076.9810312797.4453.39
Cash flow
Cash from operations56.5077.8694.3690.8264.7558.2750.17
Cash from investing51.06(41.80)(79.15)(106)(34.66)(7.96)(10.70)
Cash from financing(20.58)(27.08)(20.31)(17.12)(13.51)(10.49)(39.30)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue196177180182169143173172
Revenue growth (YoY)+15.9%+23.6%+4.2%+5.5%+2.1%+12.7%+12.4%+12.1%
Other income4.1613.463.4115.765.231153.311.94
Total expenses152144149143133118124154
EBITDA43.5832.8731.3439.0335.4725.4949.1618.63
EBITDA margin+22.3%+18.6%+17.4%+21.5%+21.0%+17.8%+28.5%+10.8%
Depreciation5.905.745.385.225.145.375.465.31
Interest0.630.390.250.120.130.180.120.17
Profit before tax41.2140.2029.1249.4535.4313546.8915.09
Tax10.6410.306.9912.609.1417.5511.9610.89

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 25 Sep 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue196177180182169143173
Revenue growth (YoY)+15.9%+23.6%+4.2%+9997.0%+9997.0%+9997.0%+9997.0%
Other income4.7013.503.4115.765.231153.31
EBITDA43.2932.8331.3439.0335.4725.4949.16
EBITDA margin+22.1%+18.6%+17.4%+21.5%+21.0%+17.8%+28.5%
Depreciation5.905.745.385.225.145.375.46
Interest0.630.390.250.120.130.180.12
Profit before tax41.4640.2029.1249.4535.4313546.89
Tax10.7010.306.9912.609.1417.5511.96
Net profit30.7629.9022.1336.8526.2911734.93
EPS (₹)18.6018.0813.3822.2815.9070.9621.12
ParticularsFY 2025-26FY 2024-25
Revenue708653
Revenue growth+14.0%+9997.0%
Other income50.33112
Total expenses580509
Employee cost141126
EBITDA127144
EBITDA margin+18.0%+22.1%
Depreciation21.4821.43
Interest1.771.59
Profit before tax154233
Tax39.0349.64
Net profit110116
Net profit margin+15.5%+17.7%
EPS (₹)69.64110.80
ParticularsFY 2025-26FY 2024-25
Equity & liabilities
Share capital13.2313.23
Reserves & surplus592517
Shareholders' funds (net worth)605531
Minority interest0.000.00
Secured loans20.000.00
Unsecured loans0.000.00
Total debt20.000.00
Total liabilities636538
Assets
Gross block321276
Net block197172
Capital work in progress23.2916.06
Investments84.91127
Inventories12492.98
Sundry debtors11786.76
Cash & bank balances192140
Loans & advances43.5020.00
Total current assets476339
Total current liabilities154120
Net working capital322220
Total assets636538
ParticularsFY 2025-26FY 2024-25
Opening cash28.7019.72
Net cash from operating activities56.5077.86
Net cash from investing activities85.84(41.80)
Net cash from financing activities(20.58)(27.08)
Net change in cash1228.98
Closing cash192140
ParticularsFY 2025-26FY 2024-25
Growth
Sales growth+8.3%+9997.0%
EBITDA growth-11.9%+9997.0%
PBT growth-33.8%+9997.0%
Net income growth-5.1%+9997.0%
Profitability & leverage
Net income margin+16.3%+28.0%
Return on capital employed+26.6%+27.6%
Return on net worth+20.3%+21.8%
Debt / equity0.020.00
Long-term debt / equity0.010.00
Interest cover1.681.29
Efficiency & per share
Fixed asset turnover2.372.37
Inventory turnover6.537.03
Debtors turnover6.967.53
EPS (₹)69.64110.80
Dividend per share (₹)24.0024.00
Book value per share (₹)366.05320.80
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue196177180182169143173172
Revenue growth (YoY)+15.9%+23.6%+4.2%+5.5%+2.1%+12.7%+12.4%+12.1%
Other income4.1613.463.4115.765.231153.311.94
Total expenses152144149143133118124154
EBITDA43.5832.8731.3439.0335.4725.4949.1618.63
EBITDA margin+22.3%+18.6%+17.4%+21.5%+21.0%+17.8%+28.5%+10.8%
Depreciation5.905.745.385.225.145.375.465.31
Interest0.630.390.250.120.130.180.120.17
Profit before tax41.2140.2029.1249.4535.4313546.8915.09
Tax10.6410.306.9912.609.1417.5511.9610.89
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue708653582513440389376
Revenue growth+14.0%+12.4%+10.7%+16.0%+10.9%-0.8%+8.5%
Other income50.291127.214.802.990.910.73
Total expenses580509453409353318321
Employee cost14112613211799.9794.6690.97
EBITDA12714412910487.2570.9354.84
EBITDA margin+18.0%+22.1%+22.2%+20.2%+19.8%+18.2%+14.6%
Depreciation21.4821.4317.0715.5015.6616.4716.36
Interest1.771.591.441.151.411.792.76
Profit before tax15423311891.6873.1753.5836.45
Tax39.0349.6430.1824.0421.6913.587.44
Net profit11011686.8968.2150.8740.0132.94
Net profit margin+15.5%+17.7%+14.9%+13.3%+11.6%+10.3%+8.8%
EPS (₹)69.64110.8053.0140.9031.1324.1917.54
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital13.2313.2313.2313.2313.2313.2313.23
Reserves & surplus592517362294243203163
Shareholders' funds (net worth)605531375308256216177
Secured loans20.000.000.000.010.220.266.52
Unsecured loans0.000.000.000.000.721.765.20
Total debt20.000.000.000.010.942.0211.72
Total liabilities636538382315263225194
Assets
Gross block321276222220186180174
Net block197172114124104113123
Capital work in progress23.2916.0696.3125.4431.0611.779.98
Investments12012791.1658.430.000.000.00
Inventories12492.9810195.0582.9958.3346.61
Sundry debtors11786.7649.1337.4332.9957.4263.33
Cash & bank balances15714036.4757.0470.2640.751.11
Loans & advances43.4920.0021.3416.1020.6719.3514.73
Total current assets441339208206207176126
Total current liabilities15412013110379.4778.4172.39
Net working capital28722076.9810312797.4453.39
Total assets636538382315263225194
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash28.7019.7224.8256.9440.360.540.37
Net cash from operating activities56.5077.8694.3690.8264.7558.2750.17
Net cash from investing activities51.06(41.80)(79.15)(106)(34.66)(7.96)(10.70)
Net cash from financing activities(20.58)(27.08)(20.31)(17.12)(13.51)(10.49)(39.30)
Net change in cash86.988.98(5.10)(32.11)16.5839.820.17
Closing cash15714036.4757.0470.2640.751.11
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+8.3%+12.3%+13.5%+16.5%+13.1%+3.6%+13.8%
EBITDA growth-11.9%+11.7%+24.7%+18.7%+23.0%+29.3%+59.3%
PBT growth-33.8%+97.6%+28.5%+25.3%+36.6%+47.0%+142.2%
Net income growth-5.1%+33.0%+27.4%+34.1%+27.1%+21.5%+203.6%
Revenue CAGR (3Y)+11.3%+14.1%+14.4%+10.9%+10.1%+4.2%+8.6%
EBITDA CAGR (3Y)+7.1%+18.3%+22.1%+23.6%+36.3%+22.7%+23.8%
Profitability & leverage
Net income margin+16.3%+28.0%+15.1%+13.2%+11.7%+10.3%+7.7%
Return on capital employed+26.6%+32.3%+34.3%+32.2%+30.6%+26.4%+22.5%
Return on net worth+20.3%+25.5%+25.7%+24.0%+21.8%+20.4%+19.5%
Debt / equity0.020.000.000.000.010.030.14
Long-term debt / equity0.010.000.000.000.000.010.02
Interest cover1.671.291.281.311.973.297.17
Efficiency & per share
Fixed asset turnover2.372.632.642.522.402.202.23
Inventory turnover6.536.745.945.766.237.428.57
Debtors turnover6.969.6213.4514.569.746.457.35
EPS (₹)69.64110.8053.0140.9031.1324.1917.54
Dividend per share (₹)24.0024.0016.0012.009.607.204.00
Book value per share (₹)366.06320.80226.67186.00154.66130.88106.77
Want more history and ratios?
You're viewing the latest exchange-filed financials for Rpg Life Sciences Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Rpg Life Sciences Limited

As per the shareholding pattern for the quarter ended Jun 2026, promoters hold 73.00%, foreign institutional investors hold 1.00%, domestic institutional investors hold 8.60%, retail and other public shareholders hold 17.40% of Rpg Life Sciences Limited.

Promoters: 73.00%DII (Domestic Institutional): 8.60%FII (Foreign Institutional): 1.00%Retail & Others: 17.40%
Jun 2026
QUARTER
73.00% Promoters
8.60% DII (Domestic Institutional)
1.00% FII (Foreign Institutional)
17.40% Retail & Others
Promoter holding - history
Now 73.00% · Jun 2026High 73.00% · Sep 2025Low 73.00% · Sep 2025
72%72.5%73%73.5%74%Sep 2025Dec 2025Mar 2026Jun 2026Sep 2025: 73.00%Dec 2025: 73.00%Mar 2026: 73.00%Jun 2026: 73.00%73.00%73.00%
Shareholding trend - last 6 quarters
Jun 2026Mar 2026Dec 2025Sep 2025
Promoters73.00%73.00%73.00%73.00%
Public27.00%27.00%27.00%27.00%

Charges & Borrowings of Rpg Life Sciences Limited

Open charges
₹65.92 Cr
Satisfied charges
₹71.07 Cr
Breakdown by lending institutions
Others₹65.92 Cr
Latest charge details
DateLenderAmountStatus
12 Sep 2009 Others ₹65.92 Cr Open
12 Apr 2017 Others ₹20 Cr Satisfied
25 Jan 2012 Export Import Bank of India ₹7.55 Cr Satisfied
28 Jan 2011 Export-Import Bank of India ₹7 Cr Satisfied
14 Jul 2010 Export Import Bank of India ₹3.4 Cr Satisfied

Total charge records: 10 View all charges

Employees and EPFO Compliance at Rpg Life Sciences Limited

Rpg Life Sciences Limited has a workforce of 1,197 employees as of Apr 01, 2024.

Employee count
1,197
Active EPFO establishments
2
Employee growth
-1.4%
Premium access

Employee and EPFO history for Rpg Life Sciences Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Rpg Life Sciences Limited

Premium access

GST registrations and filing compliance for Rpg Life Sciences Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Rpg Life Sciences Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Rpg Life Sciences Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Rpg Life Sciences Limited

Premium access

MSME payment history for Rpg Life Sciences Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Rpg Life Sciences Limited

Premium access

Corporate group structure for Rpg Life Sciences Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Rpg Life Sciences Limited

Premium access

MCA filings and documents for Rpg Life Sciences Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Rpg Life Sciences Limited

Directors
29 Apr 2026
Pratit Prahalad Samdani was appointed as a Additional Director on 29 Apr 2026 & has been associated with this company since 4 months 30 days.
Directors
27 Dec 2025
Amol Narayan Lone was appointed as a Cfo on 27 Dec 2025 & has been associated with this company since 9 months.
Charges
29 Oct 2025
A charge with Others of Rs. 65.92 Cr registered on 12 Sep 2009 with Charge ID 10181270 was modified on 29 Oct 2025.
Activity
16 Jul 2025
Rpg Life Sciences Limited last Annual general meeting of members was held on 16 Jul 2025 as per latest MCA records.
Directors
01 May 2025
Yugal Kishor Chothuram Sikri was appointed as a Director on 01 May 2025 & has been associated with this company since 1 year 4 months.
Directors
01 May 2025
Ashok Nair was appointed as a Managing Director on 01 May 2025 & has been associated with this company since 1 year 4 months.

Recent News on Rpg Life Sciences Limited

Stocks that will see action: January 24, 2025
24 Jan 2025 · Thehindubusinessline

Frequently Asked Questions about Rpg Life Sciences Limited

Rpg Life Sciences Limited is an active public limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 29 March 2007 (19+ years old) and is registered under CIN L24232MH2007PLC169354. Listed on BSE: 532983 and NSE: RPGLIFE. The company has 1,197 employees.

Rpg Life Sciences Limited reported revenue of ₹707.52 Cr for FY 2025-26 (up 8.28% YoY) based on consolidated financials.

The current directors of Rpg Life Sciences Limited are:

The primary industry of Rpg Life Sciences Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.

Yes. Rpg Life Sciences Limited is listed on both BSE (code: 532983) and NSE (symbol: RPGLIFE).

Rpg Life Sciences Limited can be reached at the registered office: Rpg House 463 Dr. Annie Besant Road Worli, Mumbai, Maharashtra, India – 400030, or through the website rpglifesciences.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available